{"preliminary_commentary":{"by_channel":{"x_thread":7,"podcast":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03693170\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["encorafenib","binimetinib","cetuximab"]],"indication":"previously untreated BRAF V600E-mutant metastatic colorectal cancer","name":"ANCHOR CRC","nct_id":"NCT03693170","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=anchor-crc-nct03693170. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ANCHOR-CRC","arms":[{"description":"encorafenib plus binimetinib plus cetuximab","label":"1 Arm","type":"EXPERIMENTAL"}],"collaborators":["Pfizer","Merck KGaA, Darmstadt, Germany"],"completion_date":{"date":"2023-04-27","type":"ACTUAL"},"conditions":["BRAF V600E-mutant Metastatic Colorectal Cancer"],"enrollment":{"count":95,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"encorafenib","otherNames":["Braftovi"],"type":"DRUG"},{"name":"Binimetinib","otherNames":["Mektovi"],"type":"DRUG"},{"name":"Cetuximab","otherNames":["Erbitux"],"type":"DRUG"}],"last_update":"2026-07-16","lead_sponsor":"Pierre Fabre Medicament","official_title":"Phase II, Open-label, Single Arm, Multicenter Study of Encorafenib, Binimetinib Plus Cetuximab in Subjects With Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2020-06-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"Confirmed Overall Response Rate (cORR) Based on Local Tumor Assessments","timeFrame":"From initiation of treatment to disease progression up to a maximum of 17.6 months."}],"references":[{"citation":"Van Cutsem E, Taieb J, Yaeger R, Yoshino T, Grothey A, Maiello E, Elez E, Dekervel J, Ross P, Ruiz-Casado A, Graham J, Kato T, Ruffinelli JC, Andre T, Carriere Roussel E, Klauck I, Groc M, Vedovato JC, Tabernero J. ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer. J Clin Oncol. 2023 May 10;41(14):2628-2637. doi: 10.1200/JCO.22.01693. Epub 2023 Feb 10.","pmid":"36763936","type":"DERIVED"}],"start_date":{"date":"2019-01-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer","url":"https://clinicaltrials.gov/study/NCT03693170"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/anchor-crc-nct03693170"}